Lipid Synthesis Suppression is the active inhibition of de novo lipogenesis and fatty acid esterification pathways within key metabolic cells, particularly hepatocytes and adipocytes, often mediated by hormonal or pharmacological intervention. Clinically, this aims to reduce ectopic fat accumulation and improve systemic dyslipidemia profiles associated with metabolic dysfunction. This process directly opposes energy storage mechanisms.
Origin
This term combines ‘lipid synthesis,’ the creation of triglycerides and other fats, with ‘suppression,’ meaning to restrain or reduce the rate of the process. It is a term commonly used in metabolic research and pharmaceutical development targeting fat accumulation.
Mechanism
Suppression is frequently achieved through the activation of signaling pathways that inhibit key lipogenic enzymes, such as downregulating the activity of sterol regulatory element-binding protein 1c (SREBP-1c) or activating AMP-activated protein kinase (AMPK). Hormones like glucagon or certain pharmacological agents promote this effect to shift cellular energy substrate utilization away from storage and toward immediate oxidation.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.